Variables | EFS | OS | ||
---|---|---|---|---|
HR (95%CI) | P value | HR (95%CI) | P value | |
Gender | ||||
 Male | Ref. |  | Ref. |  |
 Female | 5.0 (1.5, 17.5) | 0.011 | 3.8 (1.2, 12.5) | 0.025 |
Age group | ||||
  < 1 | Ref. |  | Ref. |  |
  ≥ 1, < 10 | 0.3 (0.1, 1.1) | 0.072 | 0.3 (0.1, 1.3) | 0.101 |
  ≥ 10 | 0.1 (0.0, 0.8) | 0.028 | 0.2 (0.0, 2.2) | 0.183 |
Chemotherapy protocol | ||||
 GD-ALL-2008 Protocol | Ref. |  | Ref. |  |
 SCCLG-ALL-2016 Protocol | 1.2 (0.4, 3.1) | 0.745 | 1.4 (0.1, 17.6) | 0.771 |
WBC group | ||||
  < 50 × 109/L | Ref. |  | Ref. |  |
  ≥ 50 × 109/L | 2.7 (1.1, 7.1) | 0.039 | 16.9 (1.5, 185.3) | 0.021 |
Hb group | ||||
  < 110 g/L | Ref. |  | Ref. |  |
  ≥ 110 g/L | 0.8 (0.2, 3.8) | 0.797 | 1.5 (0.6, 4.0) | 0.425 |
PLT group | ||||
  < 100 × 109/L | Ref. |  | Ref. |  |
  ≥ 100 × 109/L | 0.2 (0.0, 1.9) | 0.175 | 0.6 (0.2, 1.5) | 0.260 |
Risk group | ||||
 SR | Ref. |  | Ref. |  |
 IR | 1.6 (0.3, 7.5) | 0.576 | 4.9 (0.5, 47.5) | 0.170 |
 HR | 1.8 (0.5, 6.8) | 0.399 | 1.7 (0.1, 26.8) | 0.717 |
Immunophenotype | ||||
 B -cell | Ref. |  | Ref. |  |
 T-cell | 6.7 (1.5, 29.6) | 0.012 | 2.8 (1.1, 7.1) | 0.031 |
MLL partner gene | ||||
 MLL-PTD | Ref. |  | Ref. |  |
 MLL-AF4 | 4.8 (1.4, 17.1) | 0.015 | 6.4 (1.6, 24.8) | 0.007 |
 MLL-ENL | 1.2 (0.2, 7.0) | 0.872 | 1.7 (0.1, 26.8) | 0.717 |
 Others | 0.9 (0.1, 5.3) | 0.882 | 1.2 (0.1, 19.9) | 0.883 |
Prednisone Response | ||||
 PGR | Ref. |  | Ref. |  |
 P PR | 1.8 (0.5, 6.7) | 0.399 | 2.0 (0.6, 7.4) | 0.285 |
D15 BM | ||||
 M1 | Ref. |  | Ref. |  |
 M2/M3 | 1.4 (0.4, 4.7) | 0.633 | 2.0 (0.6, 6.6) | 0.243 |
D33 BM | ||||
 M1 | Ref. |  | Ref. |  |
 M2/M3 | 1.0 (0.2, 4.2) | 0.960 | 0.5 (0.0, 9.9) | 0.683 |
D15 MRD | ||||
  < 0.1% | Ref. |  | Ref. |  |
  ≥ 0.1% | 3.6 (1.1, 12.4) | 0.041 | 5.8 (1.2, 29.0) | 0.031 |
D33 MRD | ||||
  < 0.01% | Ref. |  | Ref. |  |
  ≥ 0.01% | 0.5 (0.1, 3.8) | 0.498 | 2.1 (0.4, 10.1) | 0.360 |
SCT | ||||
 No | Ref. |  | Ref. |  |
 Yes | 0.4(0.2, 0.9) | 0.027 | 0.1 (0.0, 0.8) | 0.027 |